Authors
Latest:
FDA Gives Alzheimer’s Drug Leqembi Full Approval. That Means Medicare Coverage But...Medicare-eligible patients need to be enrolled in registry to get Medicare coverage for the anti-beta amyloid drug that is priced to cost $26,500 a year.
Latest:
Shipping Strategies in Unusual TimesThe steps pharma manufacturers can take to mitigate transportation costs amid Covid’s supply-chain crunch
Latest:
Expert: Digital Transformation is Key Part of Biopharma C-Suite Goals for 2024Stephanie L. Woerner, PhD, director and principal research scientist at the MIT Center for Information Systems Research, discusses the outlook for next year among biopharma firms.
Latest:
Unique Challenges to Market Access for Ophthalmology BiosimilarsCatherine Humphries sheds light on three key market access challenges within the ophthalmology biosimilars space.
Latest:
Healthcare Scorecard from Patients with Chronic IllnessA look at the prevailing factors impacting treatment access in 2025.
Latest:
Machine Health in Pharmaceutical ProductionPredictive maintenance in pharmaceutical production can help reduce downtime and increase efficiency. Grundfos Machine Health (GMH) uses artificial intelligence (AI)-driven wireless sensors to monitor motor health in real-time, identifying potential issues. This approach not only reduces maintenance costs but also ensures compliance with industry standards.
Latest:
Reshaped Priorities Pave Cold Chain PathHow recent advancements in practice and technology have ushered in a new era of pharmaceutical logistics.
Latest:
Beyond the Hype: GenAI’s Real Impact on Life Sciences ManufacturingTaking stock of today's gains and tomorrow's potential for generative artificial intelligence in reshaping the industry.
Latest:
Right product, right place, right awayA prescription for making the pharma supply chain more resilient, reliable and disruption-proof
Latest:
Keeping Do-Not-Freeze Injectable Drugs Safe Through the Last MileAlongside the proper temperature-monitoring technology, optimal production control is necessary for success in cold chain drug delivery.
Latest:
11 Market Access Questions to Address Prior to Launching Your First Specialty DrugWednesday, October 5, 2022, 11am EDT Market access considerations can be complex to navigate and overwhelming to address for biopharmaceutical commercial teams launching their first specialty drug. Get answers to eleven key questions that will help guide commercial teams in effectively launching specialty products.
Latest:
The Consolidated Appropriations Act and PBM TransparencyNew federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.
Latest:
The Key Steps Ahead of DSCSA D-DayA recommended checklist for manufacturers as they enlist distributor and 3PL support—and the important questions they should be asking themselves
Latest:
The Burgeoning Specialty Drug Market: A Case for Guaranteed ValueAn actionable perspective on the future of specialty drug value-based contracting
Latest:
Plan of attack for small company supplier negotiationsHow emerging life sciences organizations can create value with suppliers
Latest:
Bridging the Divide: Understanding Contrasting Approaches in Drug DevelopmentAnalyzing the divergent paths undertaken by small biotech and large pharma companies in drug development.
Latest:
Preparing for Peak Season with Temperature-controlled ContainersThe pharma logistics peak season—and most of 2022—is going to be challenging for pharmaceutical shippers, forwarders and the air cargo industry. But making slight changes—such as choosing the right packaging—can make it easier.
Latest:
Navigating the Complexities of Prescription Drug Pricing: Affordable Solutions Are Available to Self-Insured Plan SponsorsThe lack of transparency in the pharmaceutical industry further exacerbates the challenges faced by consumers.
Latest:
The CGT Evolution: Key ConsiderationsHow cell and gene therapies can be safely protected as they move along the supply chain, even when temperature-related challenges present themselves.
Latest:
High-Tech Hubs and Specialty PharmaWith the rapid rise of the specialty drug market, manufacturers are increasingly relying on new advances used by patient hubs to boost their levels of patient engagement.
Latest:
In the Shadows of the Drug Affordability Debate, Patients Pay the Ultimate PriceAll healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives.
Latest:
Strengthening the Cold Chain: Insights Gained from COVID-19A breakdown of how the industry is using these lessons to move full steam ahead.
Latest:
CSA a Game Changer for the Life Sciences?Exploring the FDA’s latest proposed guidance on computer system validation, and the movement toward a less burdensome approach
Latest:
An Economic Path Forward: Thoughts on an Industry Inflection PointThe life sciences industry is at an inflection point, with pressures around pricing, patient access, and affordability converging with the cost of increasingly complex and personalized medicines to make today’s economics unsustainable. Scott Howell and Ray Pressburger discuss what can be done to help solve these challenges across the industry.
Latest:
Strategies to Modernize, Future-Proof, and Secure the Healthcare Supply ChainEnsuring that essential treatments reach patients safely and efficiently is an increasing imperative in today's pharma landscape.
Latest:
An Economic Path Forward: Thoughts on an Industry Inflection PointThe life sciences industry is at an inflection point, with pressures around pricing, patient access, and affordability converging with the cost of increasingly complex and personalized medicines to make today’s economics unsustainable. Scott Howell and Ray Pressburger discuss what can be done to help solve these challenges across the industry.
Latest:
Tapping into Digital IntelligenceUsing technology to personalize customer engagement, build HCP trust.
Latest:
The Do’s of Evaluating Cell Sourcing PartnersFactors to keep in mind before obtaining material in the cell therapy space.
Latest:
Benefits of Structured Content in Preparing Data for Regulatory SubmissionsHow taking steps to incorporate data into all regulatory and labeling operations helps firms avoid retroactively planning to recapture information
